Cover Image
市場調查報告書

PharmaPoint:潰瘍性大腸炎(UC) - 美國的醫藥品的預測與市場分析

PharmaPoint: Ulcerative Colitis - US Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 300566
出版日期 內容資訊 英文 134 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:潰瘍性大腸炎(UC) - 美國的醫藥品的預測與市場分析 PharmaPoint: Ulcerative Colitis - US Drug Forecast and Market Analysis to 2022
出版日期: 2014年02月28日 內容資訊: 英文 134 Pages
簡介

2012年到2022年潰瘍性大腸炎(UC)治療藥市場,預測將在Johnson & Johnson(Simponi)、武田藥品工業(Entyvio)的加入下大幅成長,主要國家(美國、歐盟五國、日本、加拿大)預計接受生技藥品治療的患者數將會增加。此外由於UC的暢銷藥物(Remicade,Humira)在美國專利到期,生技仿製藥的發售有影響市場的可能性。

本報告提供美國的UC治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀
    • QOL

第4章 疾病的管理

  • 診斷和治療概要
    • 診斷
    • 治療的指南主要的處方藥
    • 臨床診療
  • 美國

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
    • Remicade(infliximab)
    • Humira(adalimumab)
    • Simponi(golimumab)
    • Apriso(mesalamine)
    • Asacol HD(mesalamine)
    • Lialda(mesalamine)
    • Pentasa(mesalamine)
    • Colazal(balsazide disodium)
    • Giazo(balsalazide disodium)
    • sfRowasa(mesalamine)
    • Uceris(budesonide)
    • 其他
  • 生技仿製藥

第6章 機會及未滿足需求

  • 概要
  • 未滿足需求
  • 未滿足需求的差距分析
  • 疾病的嚴重程度與以大腸癌生物標靶為基礎的預後工具
  • 難治性的預測因素

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
    • Entyvio(vedolizumab)
    • Xeljanz(tofacitinib)

第8章 市場預測

  • 美國

第9章 附錄

圖表

目錄
Product Code: GDHC218CFR

During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnson's (J&J's) Simponi and Takeda's Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

GlobalData estimates that by the end of the forecast period the UC market in the US will grow to approximately $3.5 billion. While the prevalence of the disease in the US will plateau during the course of the 10-year forecast period from 2012-2022, the overall patient numbers are on the rise because of the country's growing population and increasing life expectancy. This market would grow even more if Remicade and Humira were not set to lose their patent protection in 2018. Biosimilars are expected to eventually take two thirds of their branded drugs' sales in the US.

Scope

  • Overview of Ulcerative Colitis including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the US from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the US Ulcerative Colitis market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2012-2022 in Ulcerative Colitis.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
    • 3.2.1. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines and Leading Prescribed Drugs
    • 4.1.3. Clinical Practice
  • 4.2. US

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Remicade (infliximab)
    • 5.3.2. Humira (adalimumab)
    • 5.3.3. Simponi (golimumab)
    • 5.3.4. Apriso (mesalamine)
    • 5.3.5. Asacol HD (mesalamine)
    • 5.3.6. Lialda (mesalamine)
    • 5.3.7. Pentasa (mesalamine)
    • 5.3.8. Colazal (balsazide disodium)
    • 5.3.9. Giazo (balsalazide disodium)
    • 5.3.10. sfRowasa (mesalamine)
    • 5.3.11. Uceris (budesonide)
    • 5.3.12. Other Drug Classes Used in the Treatment of UC
  • 5.4. Biosimilars
    • 5.4.1. Introduction
    • 5.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.4.3. Biosimilars in the Immunology Community
    • 5.4.4. By the Numbers: Biosimilars in Development
    • 5.4.5. The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Unmet Needs
    • 6.2.1. Curative Therapy for Severe UC Patients
    • 6.2.2. Diagnostic Markers for Disease Severity
    • 6.2.3. Personalized Therapy
    • 6.2.4. A Replacement for Steroids
    • 6.2.5. Novel Oral Drug Formulations
    • 6.2.6. Preventative Medicine for Lowering the Associated Colorectal Cancer Risk
    • 6.2.7. Improved Management of Infectious Adverse Events
  • 6.3. Unmet Needs Gap Analysis
  • 6.4. Disease Severity and Colorectal Cancer Biomarker-Based Prognostic Tools
  • 6.5. Predictors of Medically-Refractory Disease

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Entyvio (vedolizumab)
    • 7.2.2. Xeljanz (tofacitinib)

8. Market Outlook

  • 8.1. United States
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed UC Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Drugs Included in Each Therapeutic Class
    • 9.4.4. Launch and Patent Expiry Dates
    • 9.4.5. General Pricing Assumptions
    • 9.4.6. Individual Drug Assumptions
    • 9.4.7. Generic Erosion
    • 9.4.8. Pricing of Pipeline Agents
  • 9.5. Physicians and Specialists Included in This Study
  • 9.6. Primary Research - Prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Author
    • 9.7.2. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Genetic Factors That Confer a Predisposition to UC
  • Table 2: Typical Symptoms of UC
  • Table 3: Truelove and Witts UC Severity Index
  • Table 4: UCDAI
  • Table 5: Treatment Guidelines for UC Used in the 10MM
  • Table 6: Most Commonly Prescribed Drugs for UC by Class in the 10MM, 2013
  • Table 7: UC Management Country Profile - US
  • Table 8: Leading Treatments for UC, 2014
  • Table 9: Product Profile - Remicade
  • Table 10: Remicade SWOT Analysis, 2014
  • Table 11: Product Profile - Humira
  • Table 12: Humira Efficacy in the ULTRA 2 Trial
  • Table 13: Product Efficacy Comparison - Humira vs. Remicade
  • Table 14: Humira SWOT Analysis, 2014
  • Table 15: Product Profile - Simponi
  • Table 16: Simponi SWOT Analysis, 2014
  • Table 17: Product Profile - Apriso
  • Table 18: Apriso SWOT Analysis, 2014
  • Table 19: Product Profile - Asacol HD
  • Table 20: Asacol HD SWOT Analysis, 2014
  • Table 21: Product Profile - Lialda
  • Table 22: Lialda SWOT Analysis, 2014
  • Table 23: Product Profile - Pentasa
  • Table 24: Pentasa SWOT Analysis, 2014
  • Table 25: Product Profile - Colazal
  • Table 26: Colazal SWOT Analysis, 2014
  • Table 27: Product Profile - Giazo
  • Table 28: Giazo SWOT Analysis, 2014
  • Table 29: Product Profile - sfRowasa
  • Table 30: sfRowasa SWOT Analysis, 2014
  • Table 31: Product Profile - Uceris
  • Table 32: Uceris SWOT Analysis, 2014
  • Table 33: Summary of Other Immunomodulators for UC, 2013
  • Table 34: Biosimilars Pipeline, 2013
  • Table 35: Overall Unmet Needs - Current Level of Attainment
  • Table 36: Corticosteroid Long-Term Side Effects
  • Table 37: Clinical Unmet Needs in UC - Gap Analysis, 2013
  • Table 38: Prognostic Markers in UC
  • Table 39: UC - Pre-Registration and Phase III Pipeline, 2014
  • Table 40: Comparison of Therapeutic Classes in Development for UC, 2014
  • Table 41: Product Profile - Entyvio
  • Table 42: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Induction of Remission in UC
  • Table 43: Results of the GEMINI I Trial, Efficacy of Vedolizumab in the Maintenance of Remission in UC
  • Table 44: Most Common Adverse Events with Vedolizumab in the GEMINI I Study
  • Table 45: Entyvio SWOT Analysis, 2014
  • Table 46: Product Profile - Xeljanz
  • Table 47: Results of Phase IIa Trial of Xeljanz in the Induction of Remission in UC
  • Table 48: Most Common Adverse Events in the Phase IIa Trial of Xeljanz
  • Table 49: Xeljanz SWOT Analysis, 2014
  • Table 50: Sales Forecasts ($m) for UC in the US, 2012-2022
  • Table 51: Key Events Impacting Sales for UC in the US, 2012-2022
  • Table 52: UC Market in the US - Drivers and Barriers, 2012-2022
  • Table 53: Key launches for Ulcerative Colitis , 2012-2022
  • Table 54: Key Patent Expiries
  • Table 55: Annual Cost of Therapy for 5-ASAs ($)
  • Table 56: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Cellular Mechanisms Involved in the Pathogenesis of UC
  • Figure 2: UC Disease Management Flowchart
  • Figure 3: Competitive Assessment of Late-Stage Pipeline Agents UC, 2012-2022
  • Figure 4: Sales for UC in the US by Drug Class, 2012-2022
Back to Top